ONCSQ (OncoSec Medical) Quick Ratio: 0.89 (As of Jan. 2023)


What is OncoSec Medical Quick Ratio?

OncoSec Medical ONCSQ -99.00% Quick Ratio is 0.89 as of Jan. 2023.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. OncoSec Medical's quick ratio for the quarter that ended in Jan. 2023 was 0.89.

OncoSec Medical has a quick ratio of 0.89. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for OncoSec Medical's Quick Ratio or its related term are showing as below:

ONCSQ's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful Quick Ratio only.

OncoSec Medical  (OTCPK:ONCSQ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


OncoSec Medical Quick Ratio Related Terms


OncoSec Medical Quick Ratio Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical Quick Ratio Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.89 5.73 2.36 6.18 2.30

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.01 4.51 2.30 1.25 0.89

ONCSQ vs NOVNQ, USRM, VRTX: Quick Ratio Comparison

For the Biotechnology subindustry, OncoSec Medical's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical Quick Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Quick Ratio distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Quick Ratio falls into.



OncoSec Medical Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

OncoSec Medical's Quick Ratio for the fiscal year that ended in Jul. 2022 is calculated as

Quick Ratio (A: Jul. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(15.232-0)/6.633
=2.30

OncoSec Medical's Quick Ratio for the quarter that ended in Jan. 2023 is calculated as

Quick Ratio (Q: Jan. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(6.442-0)/7.231
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 0.89 mean?
OncoSec Medical (ONCSQ) has a Quick Ratio of 0.89 as of Jan. 2023. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's Quick Ratio too high?
OncoSec Medical's current Quick Ratio is 0.89. The Biotechnology industry median Quick Ratio is 3.60. OncoSec Medical's value of 0.89 is 75.3% below this industry median.
How does OncoSec Medical's Quick Ratio compare to NOVNQ and USRM?
OncoSec Medical's Quick Ratio of 0.89 can be compared against companies in the Biotechnology industry. The industry median Quick Ratio is 3.60. OncoSec Medical's value of 0.89 is 75.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSec Medical's current Quick Ratio of 0.89 is 75.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on OncoSec Medical and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSec Medical's current Quick Ratio is 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current Quick Ratio of 0.89. The current Quick Ratio is 0.89 and 75.3% below the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current Quick Ratio is 0.89 as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.